Study to Detect the Predictive Capacity of a Composite Biological Marker in the Success of Embryonic Implantation in Fertilization Treatments in Vitro (IVF): Seedchrony Pilot.

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

In Vitro Fertilization (IVF) success is below 40%, with Embryo Transfer the leading cause of IVF failure. This clinical investigation aims to evaluate if the levels of an intrauterine biomarker dissolved in the uterine fluid (alone or as a complex biological marker) can predict the outcome of embryo transfer.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 37
Healthy Volunteers: t
View:

• First IVF cycle patients

• Patients who sign the informed consent form

• Patients between 18 and 37 years old.

• Patients BMI ≤ 30

• Patients who have frozen blastocysts of good quality (grade A or B)

• Patients with negative vaginal and endocervical cultures

• Patients with an antimullerian hormone level greater than 1 ng/mL.

• IVF patients with an endometrial thickness greater than 7mm with trilaminar pattern on the day of the pre-progesterone visit.

• And who meets one of these conditions:

‣ Not having had a previous embryo transfer.

⁃ Have failed only one embryo transfer

Locations
Other Locations
Spain
Vall d'Hebron Hospital
RECRUITING
Barcelona
Contact Information
Primary
Monica Rodriguez de la Vega, PhD
monica.delavega@maninamedtech.com
+34 934764928
Backup
Luis Artiles, PhD
vigilancia@maninamedtech.com
+34 934764928
Time Frame
Start Date: 2024-02-28
Estimated Completion Date: 2025-07-05
Participants
Target number of participants: 80
Treatments
Experimental: Measurement
Intrauterine biomarker will be measured twice in all enrolled patients during the frozen embryo transfer cycle: on the day before embryo transfer and on the day of embryo transfer.
Related Therapeutic Areas
Sponsors
Collaborators: Hospital Universitari Vall d'Hebron Research Institute
Leads: Manina Medtech

This content was sourced from clinicaltrials.gov